CFCharles Flexner

Charles Flexner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Charles Flexner has a total of 268 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Stated Choice Methods in Long-Acting and Extended-Release HIV Technologies: A Scoping Review of Methodological Practices and Translational Utility

    by José A. Bauermeister, Sarit Golub, Sybil Hosek, Alexandra Minnis, Karine Dubé, Christine Rael, Douglas Krakower, Willey Lin, Cody Bangcaya, Charles Flexner, et al.

    Purpose of Review: Long-acting and extended-release (LA/ER) technologies are expanding options for HIV prevention and treatment, but their population impact will depend on whether products and delivery models align with the priorities and constraints of intended users and providers. We reviewed how stated choice methods have been designed, analyzed, and used to generate implementation-relevant evidence for LA/ER technologies. Recent Findings: Fifty peer-reviewed studies published from 2020 to 2026 met inclusion criteria. Most examined HIV prevention (74%), enrolled end-users only (92%), and used discrete choice experiments or related variants (86%). Stakeholder-informed attribute sources were reported in 94%, but only 40% described dedicated, study-specific qualitative or advisory processes. Preference heterogeneity (94%), service-delivery attributes (80%), and structural access barriers (94%) were common. Only 22% included a respondent-specific status-quo comparator, 60% reported comprehension testing, and 4% achieved moderate-to-high representativeness. Although 84% examined pipeline-aligned attributes, reporting did not establish whether those attributes remained modifiable at the relevant product-lifecycle stage. Only four studies included providers, and treatment-preference research was concentrated in high-income settings. Summary: Methodological sophistication does not ensure translational utility. Stated choice studies should align their attributes, sampling, and choice architecture with the decision-maker, the product’s lifecycle stage, and the decisions still open to change. As products mature, research should prioritize actionable delivery, access, and health-system decisions and validate preferences against product experience and observed behavior.

  • Open Access

    Accelerating Generic Long‐Acting Antiretrovirals for Global HIV Treatment: Workshop Findings and a Roadmap to Access

    by Usman Arshad, Lobna Gaayeb, Henry Pertinez, Rajith K. R. Rajoli, Melynda Watkins, Parag Nimbolkar, Simone Perazzolo, Bharat Pagi, Annemarie Wensing, Saye Khoo, et al.

    The global HIV response aims for widespread availability of affordable, quality‐assured long‐acting antiretroviral (LA ARV) drugs to achieve sustained epidemic control, particularly in low‐ and middle‐income countries. This report summarizes key discussion points, findings, and outcomes from an international workshop on generic LA ARVs, held in Liverpool, United Kingdom, and co‐organized by the Long‐Acting/Extended‐Release Antiretroviral Resource Program (LEAP) and the Centre of Excellence for Long‐acting Therapeutics (CELT). The workshop brought together experts from across disciplines to evaluate the multifaceted challenges and opportunities for faster development and regulatory approval of affordable and accessible generic LA ARVs. Key topics included the application of novel pharmacokinetic end points to reduce study duration, the integration of community preferences into practice‐based research in resource‐limited settings, intellectual property considerations, formulation and manufacturing complexities that affect cost, scalability and implementation, and the growing role of model‐integrated evidence in streamlining bioequivalence assessments. To reach the goal of timely and equitable global access to long‐acting medicines, this workshop emphasized the need for strategic public‐private engagement to promote data sharing, enhance regulatory efficiencies, and develop robust in vitro–in vivo correlation strategies that meet regulatory guidance for LAI products.


  • Open Access

    The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases

    by Adeniyi Olagunju, Simone Perazzolo, Zachary R. Stephen, Mark Ryan, Xiaolin Xu, Prajith Venkatasubramanian, Shakir Atoyebi, Rachele Delle Fratte, Andrew Owen, Charles Flexner, et al.

    Long-acting (LA) therapeutics have emerged as a key component of infectious disease treatment and prevention strategies, their uptake fueled by the need to bridge notable gaps with short-acting drug formulations. In this review, we present the key drivers and summarize the enabling technologies. Focusing on infections with significant global disease burden (HIV, hepatitis B and C, tuberculosis, malaria, and COVID-19), the current state of knowledge on approved LA therapeutics and promising innovations currently in development are summarized. The potential role of LA therapeutics as countermeasures for diseases of pandemic potential and new approaches using computational modeling to accelerate their development for pediatric and perinatal health are discussed. Due to complexities in manufacturing, and the diversity of patent-protected technologies, barriers exist for global access to LA products and in upscaling intricate LA formulations. A multipronged strategic framework, including acceleration of equitable access through generic product manufacture, is proposed to realize the full potential of LA therapeutics for global health.


  • Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement

    by Simone Perazzolo, Charles W Flexner, Zachary R Stephen, Edward P Acosta, Rachel A Bender Ignacio, Rodney J Y Ho

    High-extraction protease inhibitors (eg, for human immunodeficiency virus and severe acute respiratory syndrome coronavirus 2) typically require ritonavir to enhance bioavailability by overcoming first-pass metabolism. However, in the long-acting subcutaneous injectable dosage form TLC-ART 101, lopinavir persisted in plasma for 57 days, while ritonavir was detectable for only 3–7 days. The remarkable duration of lopinavir suggests that ritonavir may be unnecessary in long-acting injectable products, potentially reducing side effects and drug–drug interactions.


  • Open Access

    Investigations of Long-Acting Formulations in Children, Adolescents, and Pregnant Women: A Systematic Review

    by Lynn Bertagnolli, Zhengyi Deng, Melissa Davy-Rothwell, Elaine J. Abrams, Charles Flexner, Ethel D. Weld

    Background/Objectives: Long-acting and extended-release drug delivery strategies have greatly improved treatment for a variety of medical conditions. Special populations, specifically infants, children, young people, and pregnant and postpartum women, could greatly benefit from access to these strategies but are often excluded from clinical trials. We conducted a systematic review of all clinical studies involving the use of a long-acting intramuscular injection or implant in infants, children, young people, and pregnant and postpartum people. Methods: Pubmed, Embase, and Cochrane Library trials were searched. Studies published from 1980 through 2018 were included. After abstract review and duplication removal, full-text articles were obtained for further review, reviewed by two independent reviewers, and disagreements were resolved by a third reviewer. Results: a total of 101 studies of long-acting therapeutics were completed in these populations, and most (80%) of these had a sample size of <100 individuals. Therapeutics for only a small pool of indications were examined in these studies, with 72% of the studies investigating hormonal contraception or other types of hormonal treatments. Only 9.3% of the studies in children and 16.7% of the studies in pregnant people collected any pharmacokinetic (PK) data. Conclusions: Long-acting formulations may behave differently (both pharmacokinetically and pharmacodynamically) in childhood, adolescence, and pregnancy as compared to non-pregnant adulthood. Therefore, it is imperative to increase and improve upon the studies investigating long-acting formulations in order to close the knowledge gap and improve care and treatment in these special populations.


  • Open Access

    Physiologically Based Pharmacokinetic Modelling of Cabotegravir Microarray Patches in Rats and Humans

    by Hannah Kinvig, Rajith K. R. Rajoli, Henry Pertinez, Lalitkumar K. Vora, Fabiana Volpe-Zanutto, Ryan F. Donnelly, Steve Rannard, Charles Flexner, Marco Siccardi, Andrew Owen

    Microarray patches (MAPs) are currently under investigation as a self-administered, pain-free alternative used to achieve long-acting (LA) drug delivery. Cabotegravir is a potent antiretroviral that has demonstrated superior results over current pre-exposure prophylaxis (PrEP) regimens. This study aimed to apply physiologically based pharmacokinetic (PBPK) modelling to describe the pharmacokinetics of the dissolving bilayer MAP platform and predict the optimal dosing strategies for a once-weekly cabotegravir MAP. A mathematical description of a MAP was implemented into a PBPK model, and empirical models were utilised for parameter estimation. The intradermal PBPK model was verified against previously published in vivo rat data for intramuscular (IM) and MAP administration, and in vivo human data for the IM administration of LA cabotegravir. The verified model was utilised for the prediction of 300 mg, 150 mg and 75 mg once-weekly MAP administration in humans. Cabotegravir plasma concentrations >4 × protein-adjusted 90% inhibitory concentration (PA-IC90) (0.664 µg/mL) and >8 × PA-IC90 (1.33 µg/mL) were set as targets. The 75 mg, 150 mg and 300 mg once-weekly cabotegravir MAP regimens were predicted to sustain plasma concentrations >4 × PA-IC90, while the 300 mg and 150 mg regimens achieved plasma concentrations >8 × PA-IC90. These data demonstrate the potential for a once-weekly cabotegravir MAP using practical patch sizes for humans and inform the further development of cabotegravir MAPs for HIV PrEP.


  • Open Access

    Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations

    by Paul Curley, James J. Hobson, Neill J. Liptrott, Edward Makarov, Amer Al-Khouja, Lee Tatham, Christopher A. W. David, Helen Box, Megan Neary, Joanne Sharp, et al.

    Long-acting injectable (LAI) formulations promise to deliver patient benefits by overcoming issues associated with non-adherence. A preclinical assessment of semi-solid prodrug nanoparticle (SSPN) LAI formulations of emtricitabine (FTC) is reported here. Pharmacokinetics over 28 days were assessed in Wistar rats, New Zealand white rabbits, and Balb/C mice following intramuscular injection. Two lead formulations were assessed for the prevention of an HIV infection in NSG-cmah−/− humanised mice to ensure antiviral activities were as anticipated according to the pharmacokinetics. Cmax was reached by 12, 48, and 24 h in rats, rabbits, and mice, respectively. Plasma concentrations were below the limit of detection (2 ng/mL) by 21 days in rats and rabbits, and 28 days in mice. Mice treated with SSPN formulations demonstrated undetectable viral loads (700 copies/mL detection limit), and HIV RNA remained undetectable 28 days post-infection in plasma, spleen, lung, and liver. The in vivo data presented here demonstrate that the combined prodrug/SSPN approach can provide a dramatically extended pharmacokinetic half-life across multiple preclinical species. Species differences in renal clearance of FTC mean that longer exposures are likely to be achievable in humans than in preclinical models.


  • Open Access

    The LEAP Process: Streamlining the Development of Long-Acting Products and Formulations for Infectious Diseases

    by Charles Flexner, Marco Siccardi, Fazila Bunglawala, Andrew Owen

    Developing long-acting products and formulations for infectious diseases is a nontrivial undertaking that is frequently classified as high risk and low reward by the pharmaceutical industry. The Long-Acting/Extended Release Antiretroviral Research Resource Program (LEAP) was founded in 2015 with the support of the National Institutes of Health to encourage, promote, and accelerate the development of such products. Assessment methodology for any new proposal brought to this group is part of a framework—the LEAP Process—that includes a landscape analysis of what is currently available in the public domain. This is followed by in silico modeling and simulation offered as a service to the relevant scientific community. A variety of preclinical and clinical outcome metrics are applied to each new agent as part of a continuous feedback loop to improve product characteristics. This allows us to catalog knowledge gaps and barriers that can be addressed by engaged stakeholders. Results are communicated in scientific articles, reviews, and position papers. This undertaking serves to de-risk discovery, development, and implementation by bridging the gaps between academic, regulatory, and industrial investigators, and by engaging those in the community who will be the eventual users of these medicines. The LEAP Process has supported formulations now approved for human immunodeficiency virus, as well as products in clinical and preclinical development for tuberculosis and hepatitis viruses B and C.


  • Open Access

    What Clinicians Need to Know About the Development of Long-Acting Formulations

    by Charles Flexner, David L Thomas, Polly Clayden, Susan Swindells

    We encourage readers of this Supplement to find articles that are relevant to the current and future practice of infectious diseases medicine. Access to long-acting products and formulations in low- and middle-income countries remains a key determinant of the impact of these advances on global health.


  • Open Access

    Transitioning Long-Acting Products to a Generic Marketplace: What's Missing?

    by David H Brown Ripin, Kelly Catlin, Linda Lewis, Danielle Resar, Carolyn Amole, Robert C Bollinger, Charles Flexner

    Development of and increased access to generic oral medications to treat high-burden diseases including human immunodeficiency virus (HIV), tuberculosis, viral hepatitis, and malaria have had a major impact on reducing global morbidity and mortality. However, access and adherence to these life-saving treatments remains limited for some of the most vulnerable and underserved populations, for whom stigma, control, and discretion are critical to decisions around care. Current efforts to develop long-acting formulations to treat and prevent these conditions could overcome many of these barriers. However, generic manufacturing of these innovative products will be required to ensure affordable access to the communities and patients in greatest need. Strategic investments in new infrastructure will be required even before markets and manufacturing costs are clear, to ensure that access to these new products is not delayed, particularly for patients in low- and middle-income countries. Unlike conventional oral medications, long-acting products require greater investment for formulation, packaging, and delivery. The requirement for long-term bioequivalence studies will introduce additional delays in regulatory approval of generic long-acting products, and expedited approval pathways must be developed. Lessons learned from the development of long-acting hormonal contraceptives and long-acting antiretroviral products may provide a way forward.